title: Chemotherapy and late course three dimensional conformal radiotherapy for treatment of patients with stage III non- small cell lung cancer.
abstract: OBJECTIVE
  To compare the efficacy and complications of chemotherapy and late course three-dimensional conformal radiotherapy (3DCRT) in treating patients with stage III non-small cell lung cancer (NSCLC).
  
  
  METHODS
  All patients were divided into two groups: to receive chemotherapy and late course 3DCRT (3DCRT group), or chemotherapy and conventional fraction radiation (control group). In the 3DCRT-group, patients were given 6~15 MV X-rays with a total dose of 40 Gy, followed by 3DCRT, 2.5 Gy~3.0 Gy per fraction, 1 fraction/ every day, total 68 Gy~70 Gy; in the control group, with conventional fraction radiation the total dose was 64~66 Gy. The chemotherapy regimen in both cases was EP (VP-16 and DDP).
  
  
  RESULTS
  Sixty four patients with stage III NSCLC were divided into two groups: 32 patients into 3DCRT, 32 into the control group. One and 2-year survival rates in 3DCRT and control group were 87.5%, 56.3%mad 65.6%, 34.4%, respectively (P<0.05); local control rates were 90.6%, 81.3% and 65.6%, 53.1%, respectively (P<0.05).
  
  
  CONCLUSIONS
  Chemotherapy and late course 3DCRT is associated with improved survival rate in patients with stage III NSCLC with good tolerability.
authors.affiliation: Department of Radiation Oncology, The People Hospital of Taixing City, Taixing, China.
authors.forename: Yang-Chen
authors.initials: YC
authors.lastname: Liu
authors.forename: Shao-Bing
authors.initials: SB
authors.lastname: Zhou
authors.forename: Fei
authors.initials: F
authors.lastname: Gao
authors.forename: Hong-Xun
authors.initials: HX
authors.lastname: Ye
authors.forename: Ying
authors.initials: Y
authors.lastname: Zhao
authors.forename: Xiao-Xiang
authors.initials: XX
authors.lastname: Yi
authors.forename: Xin-En
authors.initials: XE
authors.lastname: Huang
authors.forename: Jin
authors.initials: J
authors.lastname: Xiang
mesh_terms: D000230:Adenocarcinoma / Q000556:secondary / Q000628:therapy; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000556:secondary / Q000628:therapy*; D002294:Carcinoma, Squamous Cell / Q000556:secondary / Q000628:therapy; D059248:Chemoradiotherapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D021621:Imaging, Three-Dimensional; D008113:Liver Neoplasms / Q000556:secondary / Q000628:therapy; D008175:Lung Neoplasms / Q000473:pathology / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D011879:Radiotherapy Dosage; D020266:Radiotherapy, Conformal